361 related articles for article (PubMed ID: 33760995)
1. Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy.
Castoldi G; Carletti R; Ippolito S; Colzani M; Barzaghi F; Stella A; Zerbini G; Perseghin G; Zatti G; di Gioia CRT
Acta Diabetol; 2021 Aug; 58(8):1059-1070. PubMed ID: 33760995
[TBL] [Abstract][Full Text] [Related]
2. Renal Anti-Fibrotic Effect of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension.
Castoldi G; Carletti R; Ippolito S; Colzani M; Barzaghi F; Stella A; Zerbini G; Perseghin G; di Gioia CRT
Am J Nephrol; 2020; 51(2):119-129. PubMed ID: 31910407
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin type-2 (AT-2)-receptor activation reduces renal fibrosis in cyclosporine nephropathy: evidence for blood pressure independent effect.
Castoldi G; di Gioia CRT; Carletti R; Roma F; Zerbini G; Stella A
Biosci Rep; 2016 Dec; 36(6):. PubMed ID: 27679859
[TBL] [Abstract][Full Text] [Related]
4. Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5/6 nephrectomised rats on high salt diet.
Zeng S; Delic D; Chu C; Xiong Y; Luo T; Chen X; Gaballa MMS; Xue Y; Chen X; Cao Y; Hasan AA; Stadermann K; Frankenreiter S; Yin L; Krämer BK; Klein T; Hocher B
Biomed Pharmacother; 2022 Feb; 146():112606. PubMed ID: 34968924
[TBL] [Abstract][Full Text] [Related]
5. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotective Effects of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension Are Mediated by the Local Reduction of Sympathetic Activity and Inflammation.
Castoldi G; Carletti R; Ippolito S; Colzani M; Pelucchi S; Zerbini G; Perseghin G; Zatti G; di Gioia CRT
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445888
[TBL] [Abstract][Full Text] [Related]
7. Analysis from the EMPA-REG OUTCOME
Mayer GJ; Wanner C; Weir MR; Inzucchi SE; Koitka-Weber A; Hantel S; von Eynatten M; Zinman B; Cherney DZI
Kidney Int; 2019 Aug; 96(2):489-504. PubMed ID: 31142441
[TBL] [Abstract][Full Text] [Related]
8. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
[TBL] [Abstract][Full Text] [Related]
10. Sodium depletion enhances fibrosis and the expression of TGF-beta1 and matrix proteins in experimental chronic cyclosporine nephropathy.
Shihab FS; Andoh TF; Tanner AM; Bennett WM
Am J Kidney Dis; 1997 Jul; 30(1):71-81. PubMed ID: 9214404
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats.
Ala M; Khoshdel MRF; Dehpour AR
Oxid Med Cell Longev; 2022; 2022():1197061. PubMed ID: 35126806
[TBL] [Abstract][Full Text] [Related]
12. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.
Kolkhof P; Hartmann E; Freyberger A; Pavkovic M; Mathar I; Sandner P; Droebner K; Joseph A; Hüser J; Eitner F
Am J Nephrol; 2021; 52(8):642-652. PubMed ID: 34111864
[TBL] [Abstract][Full Text] [Related]
13. Beneficial Effect of the SGLT2 Inhibitor Empagliflozin on Glucose Homeostasis and Cardiovascular Parameters in the Cohen Rosenthal Diabetic Hypertensive (CRDH) Rat.
Younis F; Leor J; Abassi Z; Landa N; Rath L; Hollander K; Naftali-Shani N; Rosenthal T
J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):358-371. PubMed ID: 29627992
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin attenuates inflammation, apoptosis and fibrosis in a rat model of cyclosporine-induced nephropathy.
Nam HK; Lee SJ; Kim MH; Rho JH; Son YK; Lee SM; Kim SE; Kim KH; An WS
Am J Nephrol; 2013; 37(1):7-15. PubMed ID: 23258196
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
Ojima A; Matsui T; Nishino Y; Nakamura N; Yamagishi S
Horm Metab Res; 2015 Aug; 47(9):686-92. PubMed ID: 25611208
[TBL] [Abstract][Full Text] [Related]
16. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity.
Young BA; Burdmann EA; Johnson RJ; Alpers CE; Giachelli CM; Eng E; Andoh T; Bennett WM; Couser WG
Kidney Int; 1995 Aug; 48(2):439-48. PubMed ID: 7564111
[TBL] [Abstract][Full Text] [Related]
17. Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis.
Droebner K; Pavkovic M; Grundmann M; Hartmann E; Goea L; Nordlohne J; Klar J; Eitner F; Kolkhof P
Am J Nephrol; 2021; 52(7):588-601. PubMed ID: 34515038
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin.
Pichler RH; Franceschini N; Young BA; Hugo C; Andoh TF; Burdmann EA; Shankland SJ; Alpers CE; Bennett WM; Couser WG
J Am Soc Nephrol; 1995 Oct; 6(4):1186-96. PubMed ID: 8589285
[TBL] [Abstract][Full Text] [Related]
19. Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats.
Kim S; Jo CH; Kim GH
Hypertens Res; 2019 Dec; 42(12):1905-1915. PubMed ID: 31537914
[TBL] [Abstract][Full Text] [Related]
20. Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress.
Trnovska J; Svoboda P; Pelantova H; Kuzma M; Kratochvilova H; Kasperova BJ; Dvorakova I; Rosolova K; Malinska H; Huttl M; Markova I; Oliyarnyk O; Melcova M; Skop V; Mraz M; Stemberkova-Hubackova S; Haluzik M
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
